← Back to Clinical Trials
Recruiting NCT07694141

NCT07694141 Postoperative Analgesia in Thoracic Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07694141
Status Recruiting
Phase
Sponsor Hospital Universitario de Gran Canaria Doctor Negrín
Condition Postoperative Pain Management
Study Type OBSERVATIONAL
Enrollment 160 participants
Start Date 2025-11-15
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Postoperative pain through Visual analogue scalePostoperative complications

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 160 participants in total. It began in 2025-11-15 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Analgesic management in thoracic surgery presents a particular challenge for the anesthesiologist, given the intensity of postoperative pain associated with thoracotomy, a surgical procedure that can impact respiratory function and the patient's subsequent recovery. Epidural analgesia is the gold standard. When epidural catheter placement is not feasible, erector spinae plane block is a safe alternative. The ultrasound target is easily visualized, and the injection site is far from the neuraxis, pleura, and major vascular structures. Consequently, this block has been incorporated into standard clinical practice as a treatment option for patients with complex cases or as an alternative approach when epidural catheter placement is not feasible. The primary objective of this study is to assess the effectiveness of postoperative analgesia in patients undergoing elective thoracic surgery. Study Population Design A prospective observational follow-up study will be conducted. ASA I-III patients undergoing scheduled thoracic surgery between November 1 and December 31, 2025, will be included. Their analgesic management will be based on standard clinical practice.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing thoracic surgery between July 1 and October 31, 2020. * Age over 18. * ASA I-III. * Signed informed consent Exclusion Criteria: * ASA IV-V. * Chronic opioid treatment or treatment in the Chronic Pain Unit. * Intravenous drug abuse. * Local anesthetic allergy. * Language barrier, cognitive impairment, or inability to participate in clinical assessment during the study. * BMI \<18 or \>35 kg/m2

Contact & Investigator

Central Contact

Ángel Becerra Bolaños, MD PhD

✉ angbecbol@gmail.com

📞 +34676229025

Principal Investigator

Ángel Becerra, MD PhD

PRINCIPAL INVESTIGATOR

Hospital Universitario de Gran Canaria Doctor Negrín

Frequently Asked Questions

Who can join the NCT07694141 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Postoperative Pain Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07694141 currently recruiting?

Yes, NCT07694141 is actively recruiting participants. Contact the research team at angbecbol@gmail.com for enrollment information.

Where is the NCT07694141 trial being conducted?

This trial is being conducted at Las Palmas de Gran Canaria, Spain.

Who is sponsoring the NCT07694141 clinical trial?

NCT07694141 is sponsored by Hospital Universitario de Gran Canaria Doctor Negrín. The principal investigator is Ángel Becerra, MD PhD at Hospital Universitario de Gran Canaria Doctor Negrín. The trial plans to enroll 160 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology